Who are ANXV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane, Sufentanil, topiramate, propranolol, Propofol induced sedation, Remifentanil and/or propofol, treatments for essential tremor, Propofol-based total intravenous anesthesia.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anxv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ANXV — Competitive Intelligence Brief

ANXV (ANXV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anxiolytic. Area: Psychiatry.

phase 2 anxiolytic GABA_A receptor Psychiatry Biologic Live · refreshed every 30 min

Target snapshot

ANXV (ANXV) — Annexin Pharmaceuticals AB. ANXV is a small molecule that modulates the activity of certain proteins involved in anxiety disorders.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ANXV TARGET	ANXV	Annexin Pharmaceuticals AB	phase 2	anxiolytic	GABA_A receptor
Sevoflurane, Sufentanil	Sevoflurane, Sufentanil	University of Saskatchewan	phase 3	General anesthetic, Opioid analgesic	GABA_A receptor, Mu-opioid receptor
topiramate, propranolol	topiramate, propranolol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Anticonvulsant	Voltage-dependent sodium channels, GABA_A receptor
Propofol induced sedation	Propofol induced sedation	Centre Hospitalier Universitaire de Saint Etienne	phase 3	GABA_A receptor agonist	GABA_A receptor
Remifentanil and/or propofol	Remifentanil and/or propofol	Alder Hey Children's NHS Foundation Trust	phase 3	Opioid analgesic, Sedative-hypnotic	Opioid receptors, GABA_A receptor
treatments for essential tremor	treatments for essential tremor	US Department of Veterans Affairs	phase 3	GABA_A receptor modulator	GABA_A receptor
Propofol-based total intravenous anesthesia	Propofol-based total intravenous anesthesia	The Cleveland Clinic	phase 3	GABA_A receptor agonist	GABA_A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anxiolytic class)

Annexin Pharmaceuticals AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANXV — Competitive Intelligence Brief. https://druglandscape.com/ci/anxv. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab